Is It Time to Replace Vancomycin?

The focus of the program is to discuss the utility and future of vancomycin in the treatment of complicated MRSA infections. While considered to be the “gold standard”, vancomycin is not without its issues. There are many who question its effectiveness, tolerability, safety and recommended dosing regimens. Throughout the years, there have been reports of increasing MICs and some considerable debate surrounding the most effective methodology for susceptibility testing. During the last decade we have seen the arrival of newer agents to treat complicated MRSA infections. While more convenient, these newer agents have never proven superior to the gold standard but is it time to consider these newer agents as empiric therapy given the issues that have been reported with vancomycin?

Overall learning objectives
1. Review the evidence that supports vancomycin use in the treatment of complicated MRSA infections.
2. Review the evidence that supports newer agents in the treatment of complicated MRSA infections.
3. Discuss the clinical syndromes of MRSA bacteremia and MRSA pneumonia in the context of vancomycin and newer agents.

Friday April 17, 2015
0715 – 0845
(Registration and Breakfast 0715 – 0740)
Tupper Room – PEI Convention Centre
NOTE: Maximum of 50 participants (registration required)
Register Now

Speakers

Andrew E. Simor
MD, FRCPC
Chief, Department of Microbiology
Chief, Division of Infectious Diseases
Sunnybrook Health Sciences Centre
Senior Scientist, Sunnybrook Research Institute
Professor, Departments of Laboratory Medicine & Pathobiology, and Medicine
University of Toronto,
Toronto, ON

Daniel J.G. Thirion
BPharm, MSc, PharmD, FCSHP
Clinical Full Professor
Faculté de pharmacie, Université de Montréal
Pharmacist, Royal Victoria Hospital/
McGill University Health Center
Montréal, QC

Agenda
0715 – 0740 Registration and Breakfast
0740 – 0745 Opening Remarks and Introductions
0745 – 0750 Presentation of Cases with Audience Participation
Dr Andrew Simor
0750 – 0810 Treatment of Serious MRSA Infections: What Alternatives to Vancomycin Should Be Considered?
Dr Andrew Simor
• To review current epidemiology of MRSA pneumonia and MRSA bloodstream infection in Canada
• Discuss why alternative treatments to vancomycin may be considered
0810 – 0830 Why are we still using Vancomycin?
Dr Daniel Thirion
• Describe the current evidence supporting the use of vancomycin for treatment of complicated MRSA infections
• Describe the limits of using vancomycin
0830 – 0840 Return to Cases with Audience Participation
Dr Daniel Thirion
0840 – 0845 Discussion and Closing remarks
Dr Daniel Thirion and Dr Andrew Simor

This program is sponsored by an educational grant from the Sunovion Pharmaceuticals Canada.